NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/07/2026
Voltar para busca
Dado oficial do USPTO
TCANCER
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
TCANCER
ST13
US500000079437944Classe
5, 35, 42, 44
Pedido
79437944
Registro
8309564
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
22
Atualização mais recente
09/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35, 42, 44
Data de depósito
24/04/2025
Data de registro
23/06/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/06/2026
Última transação
09/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
27
Localização do titular
DE
Examinador
CROWDER-SCHAEFER, ANDREW W
Unidade examinadora
L40
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
HS Diagnomics GmbH
Representantes
Nicholas D. Wells Legends Law Group, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Chemical products in the nature of chemical reagents for medical diagnosis; diagnostic preparations for medical use through using t-cell receptors (tcrs); diagnostic preparations for medical use; diagnostic radiopharmaceutical preparations; diagnostic reagents for medical and veterinary use in in vitro diagnosis; diagnostic substances for medical use; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detectioncancer diagnosis; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detectionindividual medical diagnosis; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detectiontumour identification; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection in oncology; diagnostic test reagents comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection for veterinary use; indicators for medical diagnosisdiagnostic preparations for medical use in vivo diagnosis; medical diagnostic reagents; medical preparations for the treatment of cancer; pharmaceutical drugs in the nature of preparations for the treatment and prevention of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment and prevention of cancer; pharmaceutical preparations for diagnosisdiagnostic agents for pharmaceutical purposes; pharmaceutical preparations for diagnostic purposesdiagnostic agents for pharmaceutical purposes; pharmaceutical preparations for individual medical diagnosisdiagnostic agents for pharmaceutical purposes; pharmaceutical preparations for medical purposes for the treatment and prevention of cancer; pharmaceutical preparations for medical test kitsdiagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in cancer diagnosis; pharmaceutical preparations for medical test kitsdiagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for individual medical diagnosis in the nature of disease detection of cancer; pharmaceutical preparations for medical test kitsdiagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in oncology for testing of bodily fluids for use in cancer; pharmaceutical preparations for medical test kitsdiagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detectioncancer; pharmaceutical preparations for suppressing tumours; pharmaceutical preparationsprotein arrays for medical diagnosis purposes for the diagnosis of diseases; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations for treating cancer; pharmaceutical productsmedical and veterinary preparationsdiagnostic preparations for medical or veterinary purposes; pharmaceuticals products for the treatment of cancer; pharmaceutical products for treating cancer; preparations for medical diagnosisdiagnostic preparations for medical use in vivo diagnosis; reactants for medical diagnosisdiagnostic preparations for medical use in in vivo diagnosis; reagents and preparations for use in the nature of diagnostic test reagents for medical purposes; reagents for diagnostic tests for medical use; medical tests and medical test kitsdiagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for profilingin particular genomic and proteomic profilingfor use in the selection of therapeutics for cancer patients; medical tests and medical test kitsdiagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for the diagnosis of diseases in the nature of cancer; medical tests and medical test kitsdiagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of cancer using t-cell receptors (tcrs) for oncological purposes; pharmaceutical preparations and medical reagents using t-cell receptors (tcrs) for oncological purposes for treating cancer; medical tests and medical test kitsdiagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of cancer using t-cell receptor (tcr) clusters for oncological purposes; pharmaceutical preparations and medical reagents using t-cell receptor (tcr) clusters for oncological purposes for treating cancer; tumour suppressing agents; immunomodulatorspharmaceutical preparations for treatment of cancer; immunostimulants; immunotherapeutic agentspharmaceutical preparations for treatment of cancer; pharmaceutical products in the nature of preparations for the treatment of autoimmune diseases and autoimmune disorderspharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of immune system related disorders
Classe 35
Maintenance of data in computer databases featuring medical patient information; maintenance of data in computer databases featuring oncological information; maintenance of data in medical computer databases; maintenance of data in computer databases
Classe 42
Blood analysis services for scientific purposes; development of database services featuring medical patient information; development of database services featuring oncological information; development of database services featuring sequenced t-cell receptors (tcrs); development of medical database services; development of database services; development of pharmaceutical preparations and medicines; research laboratory services in the medical field; maintenance of online databases for others; medical research in the field of immunologyoncologyinfectiology and vaccines; medical research servicesperforming analyses for medical research; performing chemical analyses; platform as a service (PAAS) featuring computer software platforms for use in database management and t-cell receptor (tcr) identification and characterisation; research and development of pharmaceutical preparations for treating malignant tumours; research of pharmaceuticals; research services in the field of medical analyses and diagnostics; scientific research and development in identification of tumour antigens; scientific research and development in the field of immunologyoncologyinfectiology and vaccines; scientific research and development in the field of t-cell receptors (tcrs); scientific research and development; software as a service (SAAS) featuring software for database management and use in t-cell receptor (tcr) identification and characterisation; scientific research and development services for medical and pharmaceutical purposes in the fields of immunologyoncologyinfectiology and vaccines; research and development services in connection with pharmaceutical and medical preparationsmedicine and pharmaceuticals in the fields of immunologyoncologyinfectiology and vaccines; computerised medical evaluation and diagnostic services in the nature of medical research services in the fields of immunologyoncologyinfectiology and vaccines
Classe 44
Healthcare servicescomputerised medical evaluation and diagnostic services in the fields of immunologyoncologyinfectiology and vaccines; healthcare servicescomputerised medical diagnostic services in the fields of immunologyoncologyinfectiology and vaccines
Publicações
Histórico de despachos e eventos da marca no USPTO.
22 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
23/06/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
23/06/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/05/2026
PUBO
PUBLISHED FOR OPPOSITION
05/05/2026
GPNX
NOTIFICATION PROCESSED BY IB
30/04/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/04/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
15/04/2026
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
15/04/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/04/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/04/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/04/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/04/2026
RFNT
REFUSAL PROCESSED BY IB
05/02/2026
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
18/01/2026
RFRR
REFUSAL PROCESSED BY MPU
18/01/2026
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/12/2025
CNRT
NON-FINAL ACTION WRITTEN
10/12/2025
DOCK
ASSIGNED TO EXAMINER
03/12/2025
MAFR
APPLICATION FILING RECEIPT MAILED
02/12/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/12/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
27/11/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TCANCER ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.